Who we are;

Oscotec is a clinical stage drug discovery and development company. Our mission is to create values by translating cutting edge science into innovative medicine for clinically unmet needs. We focus on discovering small molecules with a novel mechanism of action and validating the drug-target-disease hypothesis through rigorous science into clinical proof-of-concept. We aspire to become a leading “discovery engine” that provides the critical impact in developing transformative therapies that will improve patients’ lives.

What we do;

Oscotec’s clinical pipeline consists of targeted therapeutics in immunology and oncology. Our flagship program, SKI-O-703 (SYK inhibitor) is currently undergoing two Phase 2 clinical trials in rheumatoid arthritis (RA) and idiopathic thrombocytopenic purpura (ITP). Oscotec is a proud inventor/originator of lazertinib, a 3rd generation EGFR inhibitor being developed by Janssen Pharma and Yuhan Corp. for lung cancers. We are also developing SKI-G-801, a selective FLT3/AXL inhibitor for AML (Phase 1) as well as other solid tumors (preclinical). Our discovery research is focused on first-in-class targets that are implicated in cancer’s immune- and therapy-resistance and metastasis. By addressing the fundamental causes of cancer-related deaths, we strive to provide revolutionary solutions that can potentially ‘cure’ cancers.